David Brennan, AstraZeneca CEO, looks at the company's results including Results and financial performance, medicines and pipeline and outlook and strategy.
AstraZeneca's Susan Galbraith, Head of Oncology Innovative Medicines Unit, talks about the current focus areas in cancer treatment and the importance of collaborations to help...
Human bodies and developing new medicines is big business. As its latest blood-thinning blockbuster, Brilinta, finally hits US pharmacy shelves, is AstraZeneca undervalued or over...
www.euronews.com AstraZeneca's Chief Executive David Brennan is to step down at the start of June. Brennan's abrupt exit after six years running Britain's second-biggest drugmaker,...